secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-109437
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris reports positive Phase 1a TH103 data, $118M cash, net loss $43.4M in 2025
--------------------------------------------------------------------------------

- Phase 1a in nAMD showed mean 10-letter BCVA gain, 129µm CST improvement, ~95% intraretinal fluid reduction.
- TH103 plasma Cmax 27-51 fold lower than approved anti-VEGF agents; no DLTs or serious AEs observed.
- Cash, equivalents and marketable securities $118.0M as of Dec 31, 2025; funding into Q4 2027.
- Net loss $43.4M for 2025 vs $69.2M in 2024; R&D expense $30.8M, G&A $15.4M.
- Completed $50.0M oversubscribed private placement in Dec 2025; Phase 1b/2 preliminary data expected 1H 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/0001193125-26-109437-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526109437/d124100d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-109437

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer